[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-lung":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,78,120,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100570861","early-phase-1-feasibility-study-of-personalized-ultra-fractionated-stereotactic-ablative-radiotherapy-pulsar-for-cancers-of-the-central-lung-100570861",false,"NCT06712745","Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung","Inclusion Criteria:\n\n1. Age ≥ 18 years of age.\n2. Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically judged as related to the biopsied site.\n3. Stage: Tumor (ITV) 1.5 - 5 cm in maximum diameter.\n4. Tumor entirely within the 2 cm \"central zone\" or within 1 cm of the mediastinum, esophagus or proximal bronchial tree by investigator assessment.\n5. Zubrod\u002FECOG Performance Status 0-2 within 30 days prior to registration.\n6. Ability to tolerate MRI.\n7. All men, as well as women of child-bearing potential\\* must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of consent, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nNote: A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy; or\n* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\nExclusion Criteria:\n\n1. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.\n2. Plans for the patient to receive other local therapy in lung (including standard fractionated radiotherapy and\u002For surgery) while on this study, except at disease progression.\n3. Females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n4. Prior administration of anti-VEGF (vascular endothelial growth factor) therapy within 1 year.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.",[25,26],"Cancer, Lung","Metastasis",[28,29,30,31,32,33,34],"lung","central lumg","cancer","metastasis","PULSAR","non small cell lung cancer","NSCLC","RECRUITING","2026-06-24",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":39},"2025-09-19",{"date":43,"type":19},"2028-12-30",{"name":45,"class":46},"University of Texas Southwestern Medical Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":77},"100512162","phase-1-a-phase-1-study-of-cpo301-in-adult-patients-with-advanced-or-metastatic-solid-tumors-100512162","NCT05948865","A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors","A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients With Advanced or Metastatic Solid Tumors","Major Inclusion Criteria:\n\n* Age ≥18 years\n* Patients with histologically confirmed locally advanced or metastatic solid tumors who have disease progression, intolerance to prior therapy, are ineligible for available therapies, or refuse standard of care therapy in the metastatic setting.\n* In Part A, patients with solid tumors including but not limited to NSCLC (adenocarcinoma and squamous cell carcinoma), breast cancer, KRAS-wild type colorectal cancer, and head \\& neck cancer based on previous biopsy result.\n* In Part B, Cohort 1 will exclusively include NSCLC patients with documented EGFR mutations based on previous biopsy result and Cohort 2 will be patients with other cancer(s) suggested to have sensitivity to CPO301 in Part A.\n* At least 1 measurable target lesion present and documented by CT or MRI according to RECIST v1.1\n* ECOG performance status 0 or 1 at screening\n* Life expectancy \\>12 weeks\n\nMajor Exclusion Criteria:\n\n* Known, active, or uncontrolled central nervous system (CNS) metastasis or carcinomatous meningitis.\n* Has AEs due to previous anti-tumor treatments not recovered to ≤Grade 1 (except for alopecia; some tolerable chronic toxicities of Grade 2 may be excluded after consultation with the sponsor, as judged by the investigator) according to NCI-CTCAE v5.0.\n* Any serious and\u002For uncontrolled concurrent illness that may interfere with study participation\n\nPrior therapy\n\n* Received other investigational drugs or treatments within 4 weeks before the first dose of the investigational drug in the study\n* The time interval between the latest anti-tumor treatment and the first dose of the investigational drug meets the following requirements: Have received anti-tumor treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy and other clinical investigational drugs within 4 weeks before the first dose of the investigational drug; have received oral fluoropyrimidines, small molecule targeted drugs within 2 weeks before the first dose of the investigational drug; have received palliative radiotherapy or local therapy within 2 weeks before the first dose of investigational drug.\n* Had major surgery within 4 weeks before the first dose of the investigational drug in the study.",{"count":56,"type":19},132,[58],"PHASE1","The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic solid tumors.\n\nThe main questions it aims to answer are:\n\n* To assess the safety and tolerability of CPO301 at increasing doses and determine the dose to be used in the second part of the study (Part A)\n* To assess the safety and tolerability of CPO301 at the dose determined to be safe and tolerable in Part A in patients with Non-Small Cell Lung Cancer and potentially other tumor types (Part B)\n* To evaluate how quickly CPO301 is metabolized by the body (pharmacokinetics or PK)\n* To evaluate if antibodies to the study drug develop (immunogenicity)\n* To evaluate preliminary efficacy to the drug\n* To correlate preliminary efficacy with mutations in a biomarker called EGFR\n\nParticipants will:\n\n* Provide written informed consent\n* Undergo screening tests to ensure they are eligible for study treatment\n* Attend all required study visits and receive CPO301 by intravenous injection every 3 weeks until the study doctor determines study treatment should be stopped, based on how well a participant is doing on treatment\n* Be followed for progression every 3 months for up to 2 years",[61,25],"Cancer",[61,63,64,65,66],"Non-Small Cell Lung Cancer","Solid Tumors","Metastatic","Advanced","2026-03-18",{"date":69,"type":39},"2026-03-20",{"date":71,"type":39},"2023-06-06",{"date":73,"type":19},"2027-08",{"name":75,"class":76},"Conjupro Biotherapeutics, Inc.","INDUSTRY",14,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":20,"phases":88,"briefSummary":90,"conditions":91,"keywords":106,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":47},"100505180","precision-lung-cancer-survivorship-care-intervention-100505180","NCT05857995","Precision Lung Cancer Survivorship Care Intervention","Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities","KYLEADSII","Inclusion Criteria:\n\n* Have been diagnosed with lung cancer\n* Reside in a rural county as determined by a Rural Urban Continuum Code (RUC) of 4 or higher\n* Be at least 18 years of age or older\n* Be able to communicate effectively in English\n\nExclusion Criteria:\n\n* Have significant psychiatric disturbance that requires a higher level of care\n* Have substance abuse\u002Fdependence that requires a higher level of care\n* Are participating in another lung cancer survivorship care intervention\n* Have previously participated in the Kentucky LEADS Lung Cancer Survivorship Care Program",{"count":87,"type":19},300,[89],"NA","The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.",[92,93,94,95,96,25,97,98,99,100,101,102,103,104,105],"Lung Cancer","Pulmonary Neoplasm","Neoplasms, Lung","Neoplasms, Pulmonary","Neoplasm, Pulmonary","Cancers, Lung","Pulmonary Cancer","Cancer, Pulmonary","Cancers, Pulmonary","Pulmonary Cancers","Cancer of the Lung","Cancer of Lung","Pulmonary Neoplasms","Lung Cancers",[107,108,109,110],"Survivorship","Quality of Life","Behavioral Oncology","Psychosocial Oncology","2026-02-19",{"date":113,"type":39},"2026-02-23",{"date":115,"type":39},"2024-08-16",{"date":117,"type":19},"2028-03-31",{"name":119,"class":46},"Jerod L Stapleton, PhD",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":20,"phases":129,"briefSummary":130,"conditions":131,"keywords":134,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":47},"100625815","exploration-of-circulating-micrornas-as-biomarkers-of-chemo-induced-peripheral-neuropathy-a-study-in-cancer-patients-100625815","NCT07427537","Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients","miR-CIPN#1","Inclusion Criteria:\n\n* Patient treated for colorectal cancer and scheduled to receive oxaliplatin-based adjuvant chemotherapy for at least 6 cycles, or\n* Patient treated for lung cancer and scheduled to receive paclitaxel-based chemotherapy for at least 4 cycles.\n\nExclusion Criteria:\n\n* Neurodegenerative disease (e.g., Parkinson's, Alzheimer's, etc.),\n* History of stroke,\n* Pre-existing neuropathy (QLQ-CIPN20 sensory score ≥ 15\u002F100),\n* Pain (NRS ≥ 4\u002F10),\n* Pregnant or breastfeeding women,\n* Patients under guardianship, curatorship, deprived of liberty, or under legal protection",{"count":128,"type":19},90,[89],"This study aims to find out whether certain molecules in the blood, called microRNAs, are linked to how often and how severely people develop nerve damage from chemotherapy. The investigators will look at patients receiving cancer drugs known to affect the nerves, such as paclitaxel (used for lung cancer) and oxaliplatin (used for colorectal cancer).",[25,132,133],"Colon Neoplasm","Neuropathy;Peripheral",[135,136,137,138,139,140],"biomarker","colorectal cancer","lung cancer","oxaliplatin","paclitaxel","chemotherapy-induced peripheral neuropathy","2026-02-16",{"date":113,"type":39},{"date":144,"type":39},"2026-01-29",{"date":146,"type":19},"2028-07-31",{"name":148,"class":46},"University Hospital, Clermont-Ferrand",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":157,"studyType":158,"phases":4,"briefSummary":159,"conditions":160,"keywords":202,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":156,"type":19},50000,"36 Months","OBSERVATIONAL","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[161,61,162,163,164,165,166,167,168,169,170,171,25,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201],"Cancer, Metastatic","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Neuroendocrine Tumors","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Leukemia","Non Small Cell Lung Cancer","Cholangiocarcinoma","Glioblastoma","Central Nervous System Tumor","Melanoma","Urothelial Carcinoma","Bladder Cancer","Ovarian Cancer","Endometrial Cancer","Testicular Cancer","Breast Cancer","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[203,204,205,206,207,208,209,210,211,212,213,30,214,215,216],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","value based care","real world data","data analytics","2025-10-25",{"date":219,"type":39},"2025-10-28",{"date":221,"type":39},"2018-01-01",{"date":223,"type":19},"2040-06",{"name":225,"class":76},"Massive Bio, Inc.",68]